The company conducted a mock study that mimicked implementation of discovery proteomics in a clinical investigation framework.

Biognosys obtained 30 FFPE colorectal cancer (CRC) tumour specimen data from the study.

It was representative of samples obtained in clinical trials and has been investigated with the help of a targeted and a discovery proteomic strategy.

Biognosys chief operating officer Dr Claudia Escher said: “We work with many of the most innovative pharma and biotech companies, who use our discovery proteomics services to advance their early-stage research programmes.

“We increasingly see an interest in using our technology further into the clinical trial phase. We are excited about the perspective that discovery proteomics can soon be an integrated part in clinical trials, and Biognosys is dedicated to bring it to the market.”

The data was generated using the data-independent acquisition technology; a label-free mass spectrometric method that combines parallel acquisition of peptide signatures with targeted data analysis.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

As part of the study, Biognosys identified close to 9,000 proteins with median technical percentage CVs well below 10% to detect subtle changes in protein expression that may occur in tumour tissue.

Biognosys’ study lays the foundation for a discovery proteomics pipeline that can be operated and documented according to GCP guidelines.

It can be applied to support the design of better clinical trials.